FIELD: pharmaceutical industry.
SUBSTANCE: method for increasing the potency of relaxin. The composition for increasing relaxin potency contains an mRNA polynucleotide compounded in an ionizable lipid nanoparticle, where the mRNA polynucleotide contains an open reading frame encoding a relaxin-based fusion protein containing the amino acid sequence set in SEQ ID NO: 1, and an immunoglobulin (Ig) fragment, wherein the ionizable lipid nanoparticle contains an ionizable lipid, which is compound 18, having the structure.
EFFECT: increasing the relaxin potency in the subject.
9 cl, 5 tbl, 15 ex, 11 dwg
Title | Year | Author | Number |
---|---|---|---|
GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
PLANTS WITH MODIFIED CHARACTERS | 2017 |
|
RU2809117C2 |
RECOMBINANT PRODUCTION OF STEVIOL GLYCOSIDES | 2014 |
|
RU2741103C2 |
NEW O-SUCCINYL HOMOSERINE TRANSFERASE VARIANT AND METHOD FOR SYNTHESIS OF O-SUCCINYL HOMOSERINE USING SAID VARIANT | 2018 |
|
RU2747493C1 |
REDUCED NICOTINE CONVERSION INTO NORNICOTINE IN PLANTS | 2015 |
|
RU2733837C2 |
FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
Authors
Dates
2023-05-05—Published
2017-05-18—Filed